ReviewFrontiers in pediatrics2021
Preventing Cardiovascular Complications in Type 1 Diabetes: The Need for a Lifetime Approach.
Review in Frontiers in pediatrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Body Composition of Children with Type 1 Diabetes: A 20-Year Single-Center Comparative Study.Children (Basel, Switzerland) · 2026Article
- Type 1 Diabetes and Cardiovascular Risk: The Current Management Strategies.Reviews in cardiovascular medicine · 2026Review
- Highly Uncontrolled Cardiovascular Risk in Emerging Adults With Paediatric-Onset Type 1 Diabetes-A Cross-Sectional Analysis From the Diabetes Prospective Follow-Up Registry DPV.Diabetes, obesity & metabolism · 2026Article
- Effect of statins and ACE inhibitors on the metabolome in the Adolescent Type 1 Diabetes cardio-renal Intervention Trial (AdDIT) cohort.Scientific reports · 2026Article
- Beyond HbAFrontiers in endocrinology · 2026Review
- Advancements in photobiomodulation for generating functional beta cells from adipose derived stem cells in 3D culture: a comprehensive review.Stem cell research & therapy · 2025Review
- T2D-LVDD: neural network-based predictive models for left ventricular diastolic dysfunction in type 2 diabetes.Diabetology & metabolic syndrome · 2025Article
- Preventing and Managing Vascular Complications in Adolescents With Type 1 Diabetes.Journal of diabetes research · 2025Review
- Strategies for Cardiovascular Disease Prevention in Type 1 Diabetes: A Comprehensive Review.Cureus · 2024Review
- Review
- The effect of physical activity on cytokine levels in adults living with type 1 diabetes-a preliminary study.Physiological reports · 2024Article
- Type 1 diabetes management: Room for improvement.Journal of diabetes · 2023Article
- Can type 1 diabetes be an unexpected complication of obesity?Frontiers in endocrinology · 2023Review
- Cardiovascular risk management in people with type 1 diabetes: performance using three guidelines.BMJ open diabetes research & care · 2022Article
- Nine-fold higher risk of acute myocardial infarction in subjects with type 1 diabetes compared to controls in Norway 1973-2017.Cardiovascular diabetology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease (CVD) remains the main cause of morbidity and mortality in individuals with type 1 diabetes (T1D). Adolescence appears to be a critical time for the development of early subclinical manifestations of CVD, with these changes likely driven by a deterioration in glycemic control during the progression through puberty, combined with the emergence of numerous other traditional cardiometabolic risk factors (e.g., hypertension, dyslipidemia, smoking, alcohol use, obesity, etc.) which emerge at this age. Although hemoglobin A1C has long been the primary focus of screening and treatment strategies, glycemic control remains poor in youth with T1D. Furthermore, screening for cardiovascular risk factors-which are often elevated in youth with T1D-is suboptimal, and use of pharmacological interventions for hypertension and dyslipidemia remains low. As such, there is a clear need not only for better screening strategies for CVD risk factors in youth, but also early interventions to reduce these, if future CVD events have to be prevented. Accumulating evidence has recently suggested that early increases in urinary albumin excretion, even within the normal range, may identify adolescents with T1D who are at an increased risk of complications, and results from pharmacological intervention with statins and ACE inhibitors in these individuals have been encouraging. These data join a growing evidence highlighting the need for a whole-life approach to prevention starting from childhood if efforts to improve CVD outcomes and related mortality in T1D are to be maintained.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.